ReviewEuropean journal of endocrinology2025
Maturity onset diabetes of the young and beyond: the changing face of single-gene diabetes.
Review in European journal of endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Genetic spectrum and treatment implications of maturity-onset diabetes of the young in the eastern Black Sea region of Türkiye: a combined adult and pediatric cohort of 296 patients with identification of rare and novel variants.Molecular biology reports · 2026Article
- Maturity onset diabetes of the young in pregnancy: management, treatment and neonatal outcomes-a systematic review.Acta diabetologica · 2026Review
- The Genetic Landscape of Diabetes Mellitus: Lessons from Monogenic and Polygenic Forms.Life (Basel, Switzerland) · 2026Review
- Patient-derived induced pluripotent stem cells for precision modelling of monogenic beta cell disorders.Frontiers in endocrinology · 2026Review
- Identification of maturity-onset diabetes of the young through targeted next-generation sequencing in Thai patients with atypical diabetes in real-world practice.Frontiers in endocrinology · 2026Article
- Prediction of maturity-onset diabetes of the young subtypes using machine learning.Frontiers in digital health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Maturity onset diabetes of the young (MODY) is the most common form of monogenic diabetes. A genetic diagnosis can help tailor treatment. However, it is vital to test the right genes. This review discusses the need to test the correct genes and widen the genes that are included on panels while also discussing examples of genes that should be removed from panels due to insufficient evidence. This is important to ensure the maximum number of patients receive a genetic diagnosis while avoiding misdiagnosis and mistreatment. To maximize the cost-benefit of genetic testing, we need to select the right patients for genetic testing-this review discusses criteria that increase the chance of a patient having a monogenic cause of their diabetes. Reduced penetrance, where some individuals have the pathogenic genotype but do not exhibit the phenotype, is now known to be increasingly common in MODY and other monogenic disorders. This has important implications when a variant is identified in an unaffected individual. This review highlights recent work that polygenic risk may play a role in determining penetrance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.